Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474405 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
A Early Phase 1 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT04474405: Completed Early Phase 1 study of Alzheimer Disease, sponsored by Avid Radiopharmaceuticals.
NCT04474405 is a Early Phase 1 study of Alzheimer Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 36 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474405, a Early Phase 1 study of Alzheimer Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.
Primary Outcome
Brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVr), normalized to the entire cerebellum. A global cortical average volume of interest (VOI) is the average SUVr of the occipital cortex, parietal cortex, and temporal cortex. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Conditions Studied
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET Scan
- PROCEDURE Whole body PET scan
- DRUG Florbetapir F 18
- PROCEDURE Brain MRI
Study Locations (2)
California
- WCCT Global, LLC - Cypress
- Hoag Memorial Hospital Presbyterian - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-08-16 |
| Est. Completion | 2013-12-09 |
| Phase | Early Phase 1 |
What the finished NCT04474405 record still lists
NCT04474405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Flortaucipir F18 is the first listed.
NCT04474405 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04474405 about?
NCT04474405 is a clinical study titled "Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects". This early phase 1 study explored the brain uptake, retention, and safety of flortaucipir and obtained preliminary information regarding dosimetry of flortaucipir.
What is the current status of trial NCT04474405?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2013-08-16. Estimated completion is 2013-12-09.
What conditions does trial NCT04474405 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04474405?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET Scan (PROCEDURE), Whole body PET scan (PROCEDURE), Florbetapir F 18 (DRUG), Brain MRI (PROCEDURE).
Who is sponsoring clinical trial NCT04474405?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474405 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04474405's enrollment target sits among peer trials
36 236th of 306 higher than 70 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Neuroinflammation Imaging in AD
RECRUITING · Early Phase 1
-
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
RECRUITING · Early Phase 1
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI